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and risk group. The time horizon was one year, without dis-
counting. Sensitivity analysis was performed to account for
uncertainty. RESULTS: Vytorin was found to be most effective
with 90% of patients successfully treated to goal compared to
78.2%, 82.1%, and 82.2% for simvastatin, atorvastatin, and
rosuvastatin, respectively. Vytorin was the preferred strategy,
dominating other treatments at a cost of $431 annually per
patient successfully treated to goal. CONCLUSION: Using lit-
erature-derived estimates for % LDL lowering efﬁcacy, we com-
pared high-potency antilipidemics based on the percentage of
patients successfully treated to goal. Estimates were similar to
outcomes reported in clinical trials. At DoD drug acquisition
costs, Vytorin appeared to be the most cost effective.
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OBJECTIVES: In Mexico, hypertension and hypercholes-
terolemia are the main causes of cardiovascular risk and death
in adult population. Prevalence of hypertension and hypercho-
lesterolemia are estimated in 30% and 43%, respectively. The
purpose of this study was to evaluate the cost—effectiveness of
amlodipine/atorvastatin in a single pill therapy compared to
other local therapies for patients with both diseases from the
Mexican health care payer’s perspective. METHODS: We used
a ﬁve-year Markov analysis model to estimate costs and effec-
tiveness. Effectiveness measures were the % of patients with full
compliance and % of patients with fatal or non-fatal cardiovas-
cular events. Transition probabilities were obtained from inter-
national published literature. Comparators used in the model
were: amlodipine 5 mg, felodipine 5 mg, nifedipine 30 mg, cap-
topril 75 mg, enalapril 20 mg, losartan 50 mg all in combination
with pravastatin 10 mg (separate pills) vs. the comparator
amlodipine 5 mg + atorvastatin 10 mg (single-pill therapy). Esti-
mation of resource use was performed employing hospital
records from ﬁve hospitals of the Social Security Mexican Insti-
tute-IMSS in Mexico City (n = 75). They included hospitaliza-
tion, ICU, emergency, outpatient services and drugs. Costs and
effectiveness measures were discounted 3% annually. One-way
and probabilistic sensitivity analyses were performed and accept-
ability curves were constructed. RESULTS: The single-pill
therapy showed better compliance with 12.5% vs. 9.6% shown
in average by the other combinations considered (p < 0.01). This
higher compliance of the single-pill therapy yielded a signiﬁcant
reduction in the number of cardiovascular events, deaths and
expected costs (cost saving strategy). Alongside the time horizon
used, the model estimated that the single-pill therapy could save
US$2.8 per patient with both diseases. Sensitivity analyses
showed the same results. CONCLUSION: In Mexico, amlodip-
ine/atorvastatin within a single-pill showed better clinical and
economic outcomes in comparison to other combinations of
antihypertensive and statins inside an institutional setting. These
results should be considered by Mexican decision-makers in
future cost-containment policies.
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OBJECTIVES: To compare cost-effectiveness (CE) of rosuvas-
tatin (RSV) and ezetimibe/simvastatin (E/S) in patients with
treated dyslipidemia to assess achievement of treatment goals
established by Adult Treatment Panel III (ATPIII). METHODS:
Clinical data was obtained from the ﬁles of dyslipidemic patients
that attended from January 2004 to December 2005 to a Car-
diology Hospital in Mexico City. Patients treated with either
RSV 10 mg/day or E/S 10/20 mg/day and with lipid determina-
tions before (basal) and after 8 weeks of treatment were
included. The perspective of the analysis was from the point of
view of the provider, and the cost of the drugs that was obtained
by a local wholesaler (NADRO, Oct 2006). Effectiveness was
measured with subrogates end points, achieving ATPIII lipid
goals and lowering LDL-C levels. The precision of the CE esti-
mate was assessed by the bootstrap method, using 1000 re-sam-
plings and by net monetary beneﬁt approach. Horizon time was
8 weeks. Acceptability curves were built to assess uncertainty.
Sensitivity analysis included threshold, one-way and scenario
assessment. RESULTS: Ninety-eight patients received RSV (age
63.1 ± 12.4 years) and 89 patients received E/S (age 65.8 ± 12.8
years). In the RSV group 81.4% and 46.4% patients achieved
2001 and 2004 lipid goals respectively, versus 58.4% and 31.5%
E/S patients (p < 0.01). LDL-C mean percentage reduction was:
RSV −46.7 ± 13.6 versus E/S −35 ± 21.3 (p < 0.001). Average
per patient costs in USD was 94.35 for RSV (85.4–109.8) and
143.01 for E/S (127.42–161.64). RSV showed to be less costly
and more effective than E/S for achieving ATPIII goals and reduc-
ing LDL-C levels. Acceptability showed that independently of
willingness to pay, RSV is CE in 97% of scenarios compared to
E/S. Sensitivity analysis showed the robustness of results. CON-
CLUSION: On clinical practice RSV is more CE in attainment
of ATPIII goals and lowering LDL-C levels in Mexican patients.
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OBJECTIVES: To determine the lifetime costs and morbidity
associated with nonadherence to lipid-lowering and antihyper-
tensive therapy in a population of hypertensive patients with
additional cardiovascular risk factors. METHODS: A Markov
model was constructed to assess the lifetime costs and outcomes
associated with different levels of adherence to lipid-lowering
and antihypertensive therapy in a cohort of patients aged 40 to
79 years. Three adherence scenarios were considered: no treat-
ment, typical adherence, and ideal adherence. Patient charac-
teristics were modeled on those of participants in the 
Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering
Arm (ASCOT-LLA); event probabilities for coronary heart
disease and stroke were estimated using risk prediction algo-
rithms from the Framingham Heart Study. The ideal adherence
scenario modeled the experience of ASCOT-LLA patients, with
adherence levels based on those observed in the trial. The typical
adherence scenario employed real-world adherence rates and
annual transitions based on prescription records from the Cali-
fornia Medicaid system. Risk reductions for the various adher-
ence states in this scenario were drawn from clinical trials. Model
outputs included frequencies of primary and secondary heart
disease and stroke, life expectancy, and pharmacy-related and
event-speciﬁc costs in 2006 USD. RESULTS: The mean number
of events per patient was 0.738 in the no treatment scenario,
